The Uromigos
Episodes
Episode 193 ESMO 2022: PRESTO - a phase III trial of androgen annihilation in biochemically relapsed prostate cancer
11 Sep 2022
Contributed by Lukas
Rahul Aggarwal describes the results of this randomised phase III study.
Episode 192 ESMO 2022: Summary of ESMO Adjuvant RCC Trials
11 Sep 2022
Contributed by Lukas
Axel Bex summarises the ipi/nivo, pembro and atezo studies.
Episode 191 ESMO 2022: PROSPER study of neoadjuvant nivolumab in RCC
10 Sep 2022
Contributed by Lukas
Mohamed Allaf describes the results of this study from ESMO.
Episode 190: ESMO 2022 Preview
02 Sep 2022
Contributed by Lukas
Chris Sweeney joins us to talk about potential highlights.
Episode 189: The Uromigos Paper of the Month - Robotic vs open cystectomy
22 Aug 2022
Contributed by Lukas
John Kelly describes the benefits of robotic surgery.
Episode 188: The 1st Uromigos Live and Unplugged face-to-face meeting
15 Aug 2022
Contributed by Lukas
Announcing The Uromigos Unplugged, taking place in Nashville from 29th-30th September.
Episode 187: Cora Sternberg - The Uromigos Legends Series
15 Aug 2022
Contributed by Lukas
Cora Sternberg discusses her career in the next episode of the Legends series.
Episode 186: Bernard Escudier - The Uromigos Legends Series
10 Aug 2022
Contributed by Lukas
Bernard Escudier discusses his career development and work in kidney cancer.
Episode 185: The Uromigos Paper of the Month - ctDNA in prostate cancer
01 Aug 2022
Contributed by Lukas
Alex Wyatt describes this Nature paper.
Episode 184: Active surveillance in prostate cancer and the seeds of doubt
26 Jul 2022
Contributed by Lukas
Declan Murphy and Matt Cooperberg debate this controversial issue.
Episode 183: Oliver Sartor - The Uromigos Legends Series
18 Jul 2022
Contributed by Lukas
Oliver Sartor discusses his career development and work in prostate cancer.
Episode 182: ASCO Kidney Cancer Guidelines
11 Jul 2022
Contributed by Lukas
Kim Rathmell describes the highlights of these guidelines.
Episode 181: Relapsed Germ Cell Tumours
27 Jun 2022
Contributed by Lukas
Darren Feldman describes different approaches and the TIGER study.
Episode 180: Enzalutamide vs active surveillance in early prostate cancer
20 Jun 2022
Contributed by Lukas
Neil Shore describes his recent controversial paper.
Episode 179: PSMA PET for Lutetium-177 in prostate cancer
20 Jun 2022
Contributed by Lukas
Phillip Kuo discusses the biomarker to select patients for therapy.
Episode 178: ASCO 2022: Germline variants in men of African descent with prostate cancer
07 Jun 2022
Contributed by Lukas
Veda Giri gives an overview of her presentation at ASCO 2022.
Episode 177: ASCO 2022: ENZAMET survival update
05 Jun 2022
Contributed by Lukas
Ian Davis describes the implications of the study.
Episode 176: ASCO 2022: HER-2 ADCs in Bladder Cancer
05 Jun 2022
Contributed by Lukas
Matt Galski discusses data from ASCO 2022.
Episode 175: ASCO 2022: Targeting the microbiome in renal cancer
04 Jun 2022
Contributed by Lukas
Nazli Dizman describes her latest data on CBM588 in renal cancer.
Episode 174: ASCO 2022: Cell free DNA as a biomarker in bladder cancer
03 Jun 2022
Contributed by Lukas
Amir Goldkorn describes translational findings from a phase 2 bladder trial.
Episode 173: ASCO 2022: The Atlantis Trial - maintenance cabozantinib in bladder cancer
03 Jun 2022
Contributed by Lukas
Rob Jones describes cabozantinib in urothelial cancer.
Episode 172: ASCO 2022: Adjuvant everolimus in renal cancer
03 Jun 2022
Contributed by Lukas
Chris Ryan describes the results of this adjuvant study.
Episode 171: Antibody drug conjugates in bladder cancer: managing adverse effects
23 May 2022
Contributed by Lukas
Jonathan Rosenberg gives an overview of the current landscape.
Episode 170: APCCC Meeting Summary
16 May 2022
Contributed by Lukas
Silke Gillessen and Chris Sweeney summarise the meeting.
Episode 169: The Uromigos Paper of the Month - Novel neoadjuvant approaches in UC
09 May 2022
Contributed by Lukas
Syed Hussein and Sam Funt describe their studies.
Episode 168: Mechanisms of response to PD1 therapy in renal cancer
02 May 2022
Contributed by Lukas
David Braun gives an overview.
Episode 167: Highlights from EIKCS oral session
22 Apr 2022
Contributed by Lukas
Michael Staehler gives an overview of the session.
Episode 166: Prostate cancer debate: doublet vs triplet first line therapy
18 Apr 2022
Contributed by Lukas
Rana McKay and Kim Chi discuss this topic, with unexpected conclusions....
Episode 165: Paper of the Month - ENZAMET quality of life data
06 Apr 2022
Contributed by Lukas
Martin Stockler describes this paper, which shows mixed effects of enza on QOL in prostate cancer.
Episode 164: Paper of the Month - what can we learn from R3 ipilimumab/nivolumab in gastric cancer
01 Apr 2022
Contributed by Lukas
Yelena Janjigian describes ipi/nivo vs nivo chemo vs chemo in Gastric cancer - published in Nature
Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer
21 Mar 2022
Contributed by Lukas
David McDermott attempts to get his point across...again.
Episode 162: Debate - Adjuvant nivolumab for bladder cancer
14 Mar 2022
Contributed by Lukas
Matt Galski and Tom Powles take the FDA and EMA approach respectively.
Episode 161: Platinum eligibility in urothelial cancer
07 Mar 2022
Contributed by Lukas
Shilpa Gupta describes cisplatin and platinum eligibility.
Episode 160: APCCC - PMSA PET as a diagnostic
28 Feb 2022
Contributed by Lukas
Stefano Fanti describes this topic.
Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer
19 Feb 2022
Contributed by Lukas
Axel Bex discusses these topics.
Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer
19 Feb 2022
Contributed by Lukas
Fred Saad describes the results of this trial.
Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer
18 Feb 2022
Contributed by Lukas
Jonathan Rosenberg describes the results of this positive randomised trial.
Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer
18 Feb 2022
Contributed by Lukas
Petros Grivas describes the results of this phase 2 trial.
Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC
17 Feb 2022
Contributed by Lukas
Kim Chi describes the results of this randomised phase 3 study.
Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer
17 Feb 2022
Contributed by Lukas
Matthew Smith describes the results of this phase 3 trial.
Episode 153: Overview of PARP inhibition in prostate cancer
10 Feb 2022
Contributed by Lukas
Pete Nelson describes mechanism of action and current clinical application in prostate cancer
Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging
07 Feb 2022
Contributed by Lukas
Elizabeth de Vries describes her paper in Annals of Oncology.
Episode 151: Bladder Cancer ESMO Guidelines update
31 Jan 2022
Contributed by Lukas
Joaquim Bellmunt gives an overview of the changes.
Episode 150: Comparing the quality of life data in renal trials
24 Jan 2022
Contributed by Lukas
David Cella unpicks the data across these studies and makes some conclusions.
Episode 149: Treatment-free survival for ipilimumab and nivolumab
28 Dec 2021
Contributed by Lukas
David McDermott describes his Clinical Cancer Research paper on this topic.
Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer
21 Dec 2021
Contributed by Lukas
Chad Tang discusses his recent Lancet oncology paper.
Episode 147: Renal Cancer Christmas Special
17 Dec 2021
Contributed by Lukas
Toni Choueiri looks back at the year in kidney cancer.
Episode 146: Bladder Cancer Christmas Special
13 Dec 2021
Contributed by Lukas
Jonathan Rosenberg discusses 2021 and what to look out for in 2022.
Episode 145: Prostate Cancer Christmas Special
06 Dec 2021
Contributed by Lukas
Silke Gillessen and Chris Sweeney give a year in review.
Episode 144: Pembrolizumab for bladder cancer
02 Dec 2021
Contributed by Lukas
Arjun Balar discusses bladder cancer and his recent move to industry.
Episode 143: The Uromigos Paper of the Month - Determinants of anti- PD-1 response and resistance in clear cell renal cell carcinoma
17 Nov 2021
Contributed by Lukas
Samra Turajlic describes her cancer cell paper.
Episode 142: Un resumen de la reciente reunión de Uromigos en Canarias
13 Nov 2021
Contributed by Lukas
Alfonso Gómez & Guillermo de Velasco describir los aspectos más destacados de esta reunión en español
Episode 141: Movember - Past, Present and Future
05 Nov 2021
Contributed by Lukas
Sam Gledhill describes the charity and its work.
Episode 140: What is the role of ipilimumab in renal cancer?
29 Oct 2021
Contributed by Lukas
Mike Atkins discusses the role of CTLA4 inhibition in RCC.
Episode 139: The Uromigos Paper of the Month - Talazoparib in biomarker positive prostate cancer
27 Oct 2021
Contributed by Lukas
Tanya Dorff discusses this paper and the role of PARP inhibitors in prostate cancer.
Episode 138: Renal Cancer ESMO Guidelines Update
22 Oct 2021
Contributed by Lukas
Laurence Albiges gives an overview of the new ESMO RCC guidelines and Brian challenges her and Tom.
Episode 137: ESMO 2021: PEACE1 overall survival in prostate cancer
19 Sep 2021
Contributed by Lukas
Karim Fizazi describes the OS benefit of the triplet.
Episode 136: ESMO 2021: STAMPEDE Abiraterone for high-risk non-metastatic prostate cancer
19 Sep 2021
Contributed by Lukas
Gert Attard describes this practice-changing plenary data.
Episode 135: ESMO 2021: The STAR Study
19 Sep 2021
Contributed by Lukas
Intermittent VEGF TKI vs continuous phase 3 trial by Janet Brown.
Episode 134: ESMO 2021: The PRISM Study
19 Sep 2021
Contributed by Lukas
Naveen Vasudev describes a three-monthly IPI dosing with Nivo in mRCC.
Episode 133: ESMO 2021: Cabozantinib and atezolizumab in prostate cancer
18 Sep 2021
Contributed by Lukas
Neeraj Agarwal describes the phase 2 study and the phase 3 plans.
Episode 132: ESMO 2021: Pembro + sEphB4-HAS in bladder cancer
17 Sep 2021
Contributed by Lukas
Sarmad Sadeghi describes the above study at ESMO 2021.
Episode 131: ESMO 2021: The NORSE Study - Erdafitinib vs Erdafitinib/Cetrelimab
17 Sep 2021
Contributed by Lukas
Jonathan Rosenberg gives an overview.
Episode 130: Larry Einhorn - The Uromigos Legends in GU Cancer series
06 Sep 2021
Contributed by Lukas
Larry Einhorn describes the spectacular advances in testis cancer.
Episode 129: Phil Kantoff - The Uromigos Legends in GU Cancer series
02 Sep 2021
Contributed by Lukas
Phil discusses his career progression and prostate cancer.
Episode 128: APCCC - PSA relapse post prostatectomy
31 Aug 2021
Contributed by Lukas
Neha Vapiwala discusses investigations and treatment for these patients.
Episode 127: APCCC - Adjuvant radiotherapy post prostatectomy
31 Aug 2021
Contributed by Lukas
Alberto Bossi discusses the role of adjuvant therapy.
Episode 126: APCCC - germ line testing and molecular testing in prostate cancer
31 Aug 2021
Contributed by Lukas
Ros Eeles gives a clinically focused overview of this topic.
Episode 125: The Uromigos Paper of the Month - MRI screening for prostate cancer
27 Aug 2021
Contributed by Lukas
Martin Ekland discusses his NEJM and Lancet Oncology papers.
Episode 124: Dean Bajorin - The Uromigos Legends in GU Cancer series
23 Aug 2021
Contributed by Lukas
Dean Bajorin discusses developments in bladder and collaboration in testis cancer.
Episode 123: Maha Hussain - The Uromigos Legends in GU Cancer series
20 Aug 2021
Contributed by Lukas
Maha discusses her career in GU cancer with a focus on prostate cancer.
Episode 122: Nick Vogelzang - The Uromigos Legends in GU Cancer series
16 Aug 2021
Contributed by Lukas
Nick discusses his career and describes treatment advances in RCC.
Episode 121: Conflicts of Interest with the podcasts
04 Aug 2021
Contributed by Lukas
Tom, Brian and Chris discuss developments for Uromigos podcasts and growth for the future.
Episode 119: EAU - Surgery in urothelial cancer
23 Jul 2021
Contributed by Lukas
Ashish Kamat walks through ongoing issues at EAU.
Episode 118: Prostate cancer highlights at EAU
20 Jul 2021
Contributed by Lukas
Peter Albers discusses three timely prostate cancer topics from the recent EAU meeting.
Episode 117: PD1/VEGF adverse event management in renal cancer
20 Jul 2021
Contributed by Lukas
Betsy Plimack discusses the tricks of the trade.
Episode 116: Renal cancer surgery controversies at EAU
14 Jul 2021
Contributed by Lukas
Grant Stewart gives his opinion on timely RCC surgical topics surrounding the European Association of Urology meeting
Episode 112: Genomic classifier of high risk African American men with prostate cancer identifying a high-risk population
05 Jul 2021
Contributed by Lukas
Kosj Yamoah (Moffitt Cancer Center) describes the work he presented at ASCO 2021.
Episode 115: Triplet therapy for 1st line metastatic prostate cancer
01 Jul 2021
Contributed by Lukas
Eric Small is quizzed about this topic. Tom gets confused between York and Leeds.
Episode 114: Radionucleotides in prostate cancer
18 Jun 2021
Contributed by Lukas
Chris Sweeney and Silke Gillessen give their opinion of recent data.
Episode 113: ASCO 2021 Enazlutamide +/- Radium-223
18 Jun 2021
Contributed by Lukas
Silke Gillessen gives a safety update from this EORTC study focusing on fractures.
Episode 111: The randomised phase 3 CANTATA in metastatic renal cancer
08 Jun 2021
Contributed by Lukas
Nizar Tannir describes the results of this trial with a novel glutaminase inhibitor.
Episode 110: PEACE1 - Triplet therapy in prostate cancer
08 Jun 2021
Contributed by Lukas
Karim Fizazi describes the results of this randomised, potentially practice-changing trial.
Episode 109: Adjuvant pembrolizumab in renal cancer
07 Jun 2021
Contributed by Lukas
Toni Choueiri describes the KN564 study in detail.
Episode 108: Peter O'Donnell gives five year follow-up data on front line pembrolizumab in urothelial cancer
07 Jun 2021
Contributed by Lukas
Tom and Peter continue to see things differently - has the data changed things?
Episode 107: ASCO 2021: Neoadjuvant chemo/nivolumab as bladder sparing
07 Jun 2021
Contributed by Lukas
Matt Galsky describes his Phase 2 study and gives a vision of the future.
Episode 106: Summary of the three bladder sparing neoadjuvant trials at ASCO 2021
07 Jun 2021
Contributed by Lukas
Andrea Necchi gives a summary of the three abstracts.
Episode 105: A Phase 2 study of novel immune combinations (ICOS) in bladder cancer
07 Jun 2021
Contributed by Lukas
Arjun Balar discusses this and his neoadjuvant chemo/immune/RT trial.
Episode 104: Plenary Session 177lu-PSMA-617 in Prostate Cancer
06 Jun 2021
Contributed by Lukas
Mike Morris does his stuff.
Episode 103: Targeting the microbiome to increase the activity of immune therapy in renal cancer
06 Jun 2021
Contributed by Lukas
Monty Pal describes a small randomised trial of ipi/nivo plus CMB588.
Episode 102: Adjuvant therapy in melanoma - how it will help inform the renal community
28 May 2021
Contributed by Lukas
James Larkin describes learning from adjuvant immune checkpoint inhibitors in melanoma.
Episode 101: The Uromigos Paper of the Month - Belzutifan in renal cancer
26 May 2021
Contributed by Lukas
Eric Jonasch gives an overview of the recent Nature Medicine publication.
Episode 100: The Uromigos 100th Podcast - Looking to the Future
21 May 2021
Contributed by Lukas
Chris Sweeney, Kala Sridhar and David McDermott discuss the future.
Episode 99: Navigating social media from a patients' perspective
19 May 2021
Contributed by Lukas
Dena Battle is the co-founder and president of KCure and a passionate kidney cancer patient advocate.
Episode 98: Bladder cancer from a patient perspective
19 May 2021
Contributed by Lukas
Dr. Lydia Makaroff, Vice President of the World Bladder Cancer Patient Coalition, discusses key issues for bladder cancer.
Episode 97: Sacituzumab Govitecan in Bladder Cancer
04 May 2021
Contributed by Lukas
Petros Grivas discusses the recent accelerated approval and JCO paper data.
Episode 96: ODAC Bladder Cancer Accelerated Approval Meetings with Andrea Apolo
28 Apr 2021
Contributed by Lukas
Andrea Apolo discusses highlights from the April 28th meeting.
Episode 95: ODAC Overview and Bladder Accelerated Approval Meetings with Jorge Garcia
28 Apr 2021
Contributed by Lukas
Jorge Garcia discusses the pembrolizumab and atezolizumab bladder cancer dangling accelerated approvals and the ODAC process
Episode 94: EIKCS Summary of Day 1
23 Apr 2021
Contributed by Lukas
Samra Turajlic summarised the meetings and looks forward to Day 2...
Episode 93: The Uromigos Paper of the Month - A new risk classification for germ cell cancer
14 Apr 2021
Contributed by Lukas
Silke Gillessen discusses the back to back JCO papers on this topic.